Breaking News Instant updates and real-time market news.

SHLM

A. Schulman

$38.90

-0.2 (-0.51%)

, ADMS

Adamas Pharmaceuticals

$32.15

-1.88 (-5.52%)

17:26
01/08/18
01/08
17:26
01/08/18
17:26

On The Fly: After Hours Movers

UP AFTER EARNINGS: A. Schulman (SHLM), up 5.3%. ALSO HIGHER: Adamas Pharmaceuticals (ADMS), up 4.2% after it announced the U.S. launch of Gocovri... Allergan (AGN), up 0.9% after it provided preliminary results for FY18... DexCom (DXCM), up 0.1% after it provided better than expected preliminary revenue for Q4 and FY17. LOWER: Big 5 Sporting Goods (BGFV), down 17.2% after it provided a lower-than-expected outlook for Q4 earnings per share... Urban Outfitters (URBN), down 5.8% after it reported that holiday sales grew 3.6% year-over-year... e.l.f. Beauty (ELF), down 6.6% after it reconfirmed its FY17 outlook... Citi Trends (CTRN), down 4.2% after reporting 2017 holiday sales results.

SHLM

A. Schulman

$38.90

-0.2 (-0.51%)

ADMS

Adamas Pharmaceuticals

$32.15

-1.88 (-5.52%)

AGN

Allergan

$170.56

-1.73 (-1.00%)

DXCM

Dexcom

$55.44

2.18 (4.09%)

BGFV

Big 5 Sporting

$7.85

0.25 (3.29%)

URBN

Urban Outfitters

$33.74

-0.52 (-1.52%)

ELF

e.l.f. Beauty

$22.02

0.24 (1.10%)

CTRN

Citi Trends

$26.11

0.08 (0.31%)

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 09

    Jan

  • 09

    Jan

  • 06

    Feb

  • 16

    Feb

  • 26

    Feb

  • 27

    Feb

  • 25

    Mar

SHLM A. Schulman
$38.90

-0.2 (-0.51%)

01/08/18
RHCO
01/08/18
NO CHANGE
Target $37
RHCO
Hold
A. Schulman price target raised to $37 from $32 at SunTrust
SunTrust analyst Jason Freuchtel raised his price target on A. Schulman to $37 from $32 ahead of the earnings release expected later today. Freuchtel notes that while raw material pricing and Hurricane Harvey impact will be near-term headwinds, pricing will become more benign in FY18. The analyst adds that FX impact this year will be favorable and the rig count can provide more upside. Freuchtel keeps his Hold rating on A. Schulman.
10/05/17
GHSC
10/05/17
NO CHANGE
GHSC
Neutral
A. Schulman could be worth $33 to $40 in a takeout, says Seaport Global
A. Schulman traded higher on a report by the Wall Street Journal suggesting the company is working with Citigroup to explore a sale. Seaport Global analyst Michael Harrison is surprised by the timing, believing it would make more sense to fix the company before exploring strategic alternatives. He also questions who would by Schulman given Polyone (POL) and Clarient are not likely interested and private equity would be challenged given already high leverage. The analyst calculates a potential takeout price would be anywhere in the $33-$40 price range and maintains a Neutral rating.
08/25/17
LBOW
08/25/17
UPGRADE
Target $37
LBOW
A. Schulman upgraded to Buy on activist involvement at Longbow
As previously reported, Longbow upgraded A. Schulman to Buy from Neutral with a $37 price target. Analyst Dmitry Silversteyn said the involvement of activist investor Cruiser Capital who acquired 10% of the company stock is a catalyst for more rapid change in strategy and improved execution that can unlock substantial shareholder value.
08/25/17
LBOW
08/25/17
UPGRADE
LBOW
Buy
A. Schulman upgraded to Buy from Neutral at Longbow
ADMS Adamas Pharmaceuticals
$32.15

-1.88 (-5.52%)

12/19/17
PIPR
12/19/17
NO CHANGE
Target $52
PIPR
Overweight
Adamas Pharmaceuticals price target raised to $52 from $35 at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target for Adamas Pharmaceuticals to $52 saying his survey of 27 neurologists who treat a significant number of patients with epilepsy yielded "encouraging early feedback" on ADS-4101. The feedback suggests a relatively high degree of enthusiasm for a next-generation form of lacosamide, Amsellem tells investors in a research note. He views ADS-4101 as a "relatively underappreciated longer-term value driver" for Adamas and keeps an Overweight rating on the shares.
10/30/17
10/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sotheby's (BID) initiated with a Buy at Aegis. 2. Alnylam (ALNY) initiated with a Buy at FBR Capital. 3. Adamas Pharmaceuticals (ADMS) initiated with an Outperform at Evercore ISI. 4. Vipshop (VIPS) initiated with a Neutral at UBS. 5. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/17
NORL
11/29/17
INITIATION
Target $70
NORL
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Northland
Northland analyst Carl Byrnes initiated Adamas Pharmaceuticals with an Outperform and $70 price target. The analyst said Adamas' GOCOVRI is a breakthrough in treating Parkinson's patients that have developed dyskinesia as a result of long-term exposure to levodopa therapy and sees peak sales exceeding $750M.
12/13/17
COWN
12/13/17
NO CHANGE
Target $55
COWN
Outperform
Adamas Pharmaceuticals named a best idea for 2018 at Cowen
Cowen analyst Ken Cacciatore views shares of Adamas Pharmaceuticals as "meaningfully undervalued" at current levels. He calls the stock a best idea for 2018 and keeps an Outperform rating on the name with a $55 price target. The analyst is confident that Gocovri, which is now on the market, will find a "significant place" in the Parkinson's disease treatment paradigm. He says Adamas has successfully developed an extended release amantadine for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease.
AGN Allergan
$170.56

-1.73 (-1.00%)

12/19/17
FBCO
12/19/17
NO CHANGE
Target $214
FBCO
Outperform
Allergan price target lowered to $214 from $224 at Credit Suisse
Credit Suisse analyst Vamil Divan price target lowered to $214 from $224 following the company's disappointing performance during the latter part of 2017. The analyst notes that questions around base business and effect of LOEs have impacted stock, but expectations and valuation are now more reasonable. Divan reiterates an Outperform rating on the shares.
01/03/18
LEER
01/03/18
NO CHANGE
LEER
Outperform
Allergan restructuring as expected, risk to guidance low, says Leerink
Leerink analyst Seamus Fernandez says that Allergan's restructuring details announced this morning strongly suggest that the company can and will achieve its 2018 net income guidance. The analyst notes that his discussion with Allergan following today's press release confirmed that its 2018 guidance during the Q3 call did not include the impact of tax reform and that the one referenced in today's press release does not include it either. That said, since Restasis generics have not launched and appears unlikely prior to mid-2018, Fernandez believes the $15 floor guidance likely will be firmly intact with the $300-400M restructuring benefit announced today. The analyst reiterates an Outperform rating on the shares.
12/08/17
RHCO
12/08/17
NO CHANGE
Target $53
RHCO
Buy
Revance price target raised to $53 from $32 at SunTrust
SunTrust analyst John Boris raised his price target on Revance (RVNC) to $53, saying the company's RT002's clinical data is "de-risked in glabellar lines", offering significant differentiation relative to Allegan's (AGN) Botox. Boris expects GL SAKURA data to be presented in February of 2018, modeling approval by the first half of 2020. The analyst also notes that the RT0002 Phase-2 plantar fasciitis data on track for December and the initiation of Phase 3 cervical dystonia trials for Q2 of next year, keeping his Buy rating on the stock.
01/05/18
WELS
01/05/18
NO CHANGE
Target $245
WELS
Outperform
Allergan has built 'great barrier' around Botox, says Wells Fargo
Wells Fargo analyst David Maris conducted a survey of 25 plastic surgeons and dermatologists to gain insight on the changing neurotoxin landscape. The survey shows Allergan's (AGN) patient and physician loyalty programs and bundling discounts create a "great barrier" around Botox, Maris tells investors in a research note. It is unclear how significant a potential competitor Revance's (RVNC) RT002 could be to Allergan's largest product, the analyst adds. He believes that even with new innovative treatment options, Botox is expected to maintain its dominance in the neurotoxin market. Further, the analyst says that while RT002 showed statistically significant results at week 24 versus placebo, the endpoint doesn't seem not match the FDA's published guidance. Maris wonders if the data will be enough to get a six-month duration claim on the RT002 label, or if Revance is just hoping for an approval and then will point to the duration data. He keeps an Outperform rating on Allergan with a $245 price target.
DXCM Dexcom
$55.44

2.18 (4.09%)

01/05/18
WBLR
01/05/18
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom remaining 'product-of-choice' in glucose monitoring
William Blair analyst Margaret Kaczor believes Dexcom (DXCM) will remain the "product-of-choice" in glucose monitoring after Abbott (ABT) received Medicare approval for its Freestyle Libre Flash. While the approval comes six to nine months earlier than anticipated, Abbott's broader presence will likely expand patient awareness, Kaczor tells investors in a research note. She believes Dexcom is well positioned given its alerts and alarms in this "more vulnerable patient population." The analyst keeps an Outperform rating on the shares following yesterday's selloff.
01/04/18
COWN
01/04/18
NO CHANGE
Target $70
COWN
Outperform
Dexcom selling off too much on Abbott news, says Cowen
Cowen analyst Doug Schenkel believes shares of Dexcom (DXCM) are down too much after Abbott (ABT) announced Medicare reimbursement for Libre. Given Libre's dosing claim, this development was expected, though it came three months earlier than expected, Schenkel tells investors in a research note. He believes a 10% selloff "appears disproportionate" on a three month timing swing on an expected event. The analyst keeps an Outperform rating on Dexcom with a $70 price target. The stock in late morning trading is down 11% to $51.86.
01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
01/05/18
LEER
01/05/18
NO CHANGE
Target $75
LEER
Outperform
Dexcom pricing risk less bad than feared, says Leerink
Leerink analyst Danielle Antalffy says her conversation with a specialist reinforced her view that Dexcom (DXCM) will continue to warrant at least some price premium to Abbott's (ABT) Libre given its alert and alarm capabilities and what is presumably better outcomes for patients. The analyst continues to recommend buying Dexcom on yesterday's, particularly for investors with at least a six month time horizon. She reiterates an Outperform rating on the shares with a $75 price target. Antalffy sees the company's pricing risk as less bad than feared following yesterday's news of Abbott securing Medicaid approval sooner than expected for its Freestyle Libre.
BGFV Big 5 Sporting
$7.85

0.25 (3.29%)

08/02/17
DBAB
08/02/17
DOWNGRADE
Target $10
DBAB
Hold
Big 5 Sporting downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Mike Baker downgraded Big 5 Sporting Goods to Hold and halved his price target for the shares to $10 from $20. The analyst had expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." This is indicative of not only weaker industry trends but also increased competition from online channels, the analyst tells investors in a research note following Big 5's Q2 results.
08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
URBN Urban Outfitters
$33.74

-0.52 (-1.52%)

11/21/17
11/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Urban Outfitters (URBN) upgraded to Overweight from Neutral at JPMorgan with analyst Matthew Boss saying same-store sales at the company's three concepts turned positive in the third quarter for the first time since the first half of 2015. 2. Deere (DE) upgraded to Outperform from Neutral at Baird with analyst Mig Dobre noting he recently downgraded the shares on concerns another record corn crop would pressure prices and push out or moderate the recovery in North American agricultural equipment demand. He acknowledged those fears did not materialize as equipment demand in October was very strong with ag dealers pointing to emerging replacement demand in spite of low crop prices. Dobre raised his price target to $155 from $140 on Deere shares. 3. Cray (CRAY) upgraded to Buy from Hold at Craig-Hallum with analyst Chad Bennett saying he believes 2017 is likely to be the fundamental bottom in the HPC market and Cray is on the cusp of a new HPC product cycle that will last the next 4-5 years. 4. T-Mobile (TMUS) upgraded to Buy from Hold at HSBC with analyst Sunil Rajgopal saying the stock continues to outperform competitors with high single-digit growth in mobile service revenues and EBITDA. 5. Copa Holdings (CPA) upgraded to Overweight from Neutral at JPMorgan with analyst Fernando Abdalla saying the demand outlook for 2018 is promising, while management remains engaged in reducing operating costs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
RHCO
12/12/17
NO CHANGE
Target $35
RHCO
Buy
Urban Outfitters price target raised to $35 from $30 at SunTrust
SunTrust analyst Pamela Quintiliano raised her price target on Urban Outfitters to $35 after the company's quarter-to-date sales update yesterday. The analyst says the "mid-single-digit" comps growth is above consensus 2.4% and supports her view that the stock is "in the early innings of a favorable fashion cycle which likely carries well into next year, if not longer." Quintiliano keeps her Buy rating on Urban Outfitters, saying the positive early response positions the company for continued outperformance with the holiday season sales still remaining ahead.
11/27/17
KEYB
11/27/17
NO CHANGE
KEYB
Rapid erosion in physical stores may be abating, says KeyBanc
KeyBanc's research consumer team says that while online remains the key avenue for growth, the rapid erosion in physical store sales may be abating. The analyst noted that strong store checks reinforce their thesis that apparel is back, with the strongest traffic at Urban Outfitters (URBN) and lululemon (LULU). Meanwhile, Wal-Mart (WMT) was able to eschew wrist bands and had solid inventory of doorbusters, while Gap (GPS) saw strong traffic at Old Navy, they contend. Additionally, KeyBanc's team says its channel checks suggest Best Buy (BBY) continues to gain share and drove healthy traffic, while Bed Bath & Beyond (BBBY) offered slightly more aggressive, but still uninspiring, undifferentiated promotions. Moreover, they believe Conn's (CONN) maintains momentum with its credit offering, credit improvement story, and the recovery in the Hurricane Harvey impacted markets. Checks also revealed solid Beauty positioning, with Ulta Beauty (ULTA) as a winner with strong holiday positioning and good traffic on Thursday/Friday, the analysts added.
11/21/17
RHCO
11/21/17
NO CHANGE
Target $30
RHCO
Buy
Urban Outfitters price target raised to $30 from $22 at SunTrust
SunTrust analyst Pamela Quintiliano raised her price target on Urban Outfitters to $30 and kept her Buy rating after "encouraging" Q3 results that were driven by an acceleration in revenues and comps. Quintiliano says that the management has struck a "cautious" tone on Q4, but the positive trends could provide several years of upside opportunity. The analyst notes that the company is likely in the early stage of the fashion cycle, adding that high marketing costs reflects the management's confidence.
ELF e.l.f. Beauty
$22.02

0.24 (1.10%)

12/15/17
12/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. RBC Capital analyst Ross MacMillan downgraded Oracle (ORCL) to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". 2. JMP Securities analyst Andrew Boone downgraded Criteo (CRTO) to Market Perform from Outperform and Citi analyst Mark Kelley downgraded Criteo to Neutral, with both citing uncertainty around Apple's (AAPL) potential response to the company's workaround of the tech giant's Intelligent Tracking Prevention. 3. Stifel analyst Jim Duffy downgraded Fitbit (FIT) to Sell from Hold as he expects the company will remain unprofitable and burn cash in 2018. 4. JPMorgan analyst Andrea Teixeira downgraded e.l.f. Beauty (ELF) to Underweight, as she expects continued deterioration in sell-through rates in tracked channels to limit the company's ability to hit its 20%-plus long-term revenue growth target.5. Goldman Sachs analyst Jami Rubin removed Amgen (AMGN) from the Conviction Buy List but maintained a Buy rating on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
BMOC
11/09/17
NO CHANGE
Target $24
BMOC
Outperform
e.l.f. Beauty price target lowered to $24 from $38 at BMO Capital
BMO Capital analyst Shannon Coyne lowered the price target on e.l.f. Beauty to $24 after the company posted Q3 results and reduced its FY17 revenue outlook. Coyne notes some of the EPS beat was driven by a holiday sales timing shift and better-than-expected expense leverage, but the revenue guidance adjustment implies a "sharp deceleration" in Q4. The analyst keeps the Outperform rating, saying the company has significant new distribution opportunities and will benefit from new mass channel store initiatives in the long term, but warns there is a short-term risk to multiples in light of the potential "conservative" FY18 guidance.
12/15/17
JPMS
12/15/17
DOWNGRADE
Target $18
JPMS
Underweight
e.l.f. Beauty downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Andrea Teixeira downgraded e.l.f. Beauty to Underweight with an unchanged price target of $18. The analyst expects continued deterioration in sell-through rates in tracked channels to limit the company's ability to hit its 20%-plus long-term revenue growth algorithm in 2018 and potentially continue to pressure sales in 2019. He sees downside risk in the shares from current levels.
12/20/17
KEYB
12/20/17
INITIATION
KEYB
Sector Weight
e.l.f. Beauty initiated with a Sector Weight at KeyBanc
KeyBanc analyst Jason Gere started e.l.f. Beauty with a Sector Weight rating saying the valuation is full at current levels. The analyst prefers to wait for a better entry point.
CTRN Citi Trends
$26.11

0.08 (0.31%)

TODAY'S FREE FLY STORIES

EADSY

Airbus

$28.43

0.755 (2.73%)

, BA

Boeing

$340.46

2.7261 (0.81%)

12:56
01/22/18
01/22
12:56
01/22/18
12:56
Periodicals
Air Lease CEO: Airbus planning response to new Boeing jet, Reuters says »

Airbus (EADSY) intends to…

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$340.46

2.7261 (0.81%)

AL

Air Lease

$49.02

0.31 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

  • 22

    Feb

ADP

ADP

$121.44

0.54 (0.45%)

, CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

12:55
01/22/18
01/22
12:55
01/22/18
12:55
Conference/Events
Stephens enterprise software analyst holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$121.44

0.54 (0.45%)

CSOD

Cornerstone OnDemand

$40.12

0.48 (1.21%)

MSFT

Microsoft

$90.00

-0.1 (-0.11%)

ORCL

Oracle

$50.48

-0.1 (-0.20%)

PAYC

Paycom

$92.03

0.84 (0.92%)

PCTY

Paylocity

$49.99

0.33 (0.66%)

SAP

SAP

$112.50

-0.7 (-0.62%)

ULTI

Ultimate Software

$227.99

-0.84 (-0.37%)

WDAY

Workday

$114.11

0.83 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

HBI

Hanesbrands

$22.94

-0.26 (-1.12%)

12:50
01/22/18
01/22
12:50
01/22/18
12:50
Options
Hanesbrands puts and calls drawing interest Monday »

Hanesbrands puts and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.47

0.66 (1.47%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Hot Stocks
Intel found root cause for Broadwell and Haswell platform issues »

Intel's Navin Shenoy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

QD

Qudian

$12.50

0.1 (0.81%)

12:45
01/22/18
01/22
12:45
01/22/18
12:45
Options
Qudian Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$44.82

0.34 (0.76%)

12:44
01/22/18
01/22
12:44
01/22/18
12:44
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel says made good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

INTC

Intel

$44.82

0.34 (0.76%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Hot Stocks
Breaking Hot Stocks news story on Intel »

Intel recommends stopping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

BAC

Bank of America

$31.76

0.04 (0.13%)

12:43
01/22/18
01/22
12:43
01/22/18
12:43
Periodicals
Bank of America eliminates remaining free-checking eBanking accounts, WSJ says »

Bank of America has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MS

Morgan Stanley

$57.02

-0.44 (-0.77%)

12:38
01/22/18
01/22
12:38
01/22/18
12:38
Hot Stocks
Breaking Hot Stocks news story on Morgan Stanley »

Morgan Stanley says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$45.78

2.43 (5.61%)

12:35
01/22/18
01/22
12:35
01/22/18
12:35
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

12:30
01/22/18
01/22
12:30
01/22/18
12:30
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

12:25
01/22/18
01/22
12:25
01/22/18
12:25
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

OMER

Omeros

$16.70

-0.02 (-0.12%)

12:24
01/22/18
01/22
12:24
01/22/18
12:24
Hot Stocks
Omeros off highs following cautious Twitter mention »

Shares of Omeros are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

, SPX

S&P 500

12:21
01/22/18
01/22
12:21
01/22/18
12:21
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Schumer says deal reached…

SPY

SPDR S&P 500 ETF Trust

$281.54

1.125 (0.40%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$12.59

0.12 (0.96%)

12:20
01/22/18
01/22
12:20
01/22/18
12:20
Options
AMD attracts a bullish three-way spread before shares tick higher »

AMD attracts a bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

BG

Bunge

$80.40

2.84 (3.66%)

, ADM

Archer Daniels

$42.21

1.2505 (3.05%)

12:19
01/22/18
01/22
12:19
01/22/18
12:19
Recommendations
Bunge, Archer Daniels, Glencore analyst commentary  »

Credit Suisse says Archer…

BG

Bunge

$80.40

2.84 (3.66%)

ADM

Archer Daniels

$42.21

1.2505 (3.05%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

$NSD

NASDAQ Market Internals

12:17
01/22/18
01/22
12:17
01/22/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/22/18
01/22
12:16
01/22/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.78

0.16 (0.24%)

12:15
01/22/18
01/22
12:15
01/22/18
12:15
Options
Kellogg put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

12:10
01/22/18
01/22
12:10
01/22/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

12:08
01/22/18
01/22
12:08
01/22/18
12:08
General news
On The Fly: Top stock stories at midday »

Stocks opened mixed, with…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

JUNO

Juno Therapeutics

$67.81

-3.56 (-4.99%)

VR

Validus

$67.50

20.775 (44.47%)

SNY

Sanofi

$43.23

-1.37 (-3.07%)

CELG

Celgene

$102.65

0.93 (0.91%)

AIG

AIG

$61.03

-0.525 (-0.85%)

IDRA

Idera Pharmaceuticals

$2.55

0.145 (6.03%)

BCRX

BioCryst

$5.59

-0.09 (-1.58%)

SANM

Sanmina

$35.45

0.5 (1.43%)

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

FE

FirstEnergy

$33.23

3.83 (13.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 02

    Feb

  • 09

    Feb

  • 14

    Feb

  • 16

    Feb

  • 20

    Feb

  • 21

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

  • 30

    Jun

  • 30

    Jun

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Periodicals
Senators have enough votes to end government shutdown, NBC reports 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$281.18

0.765 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$64.11

1.36 (2.17%)

, SNY

Sanofi

$43.22

-1.385 (-3.11%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
Hemophilia makers jump after Sanofi acquires peer Bioverativ for huge premium »

Shares of drug companies…

BIVV

Bioverativ

$64.11

1.36 (2.17%)

SNY

Sanofi

$43.22

-1.385 (-3.11%)

PFE

Pfizer

$36.88

-0.06 (-0.16%)

JNJ

Johnson & Johnson

$147.21

-0.15 (-0.10%)

ALNY

Alnylam

$124.83

0.84 (0.68%)

CBIO

Catalyst Biosciences

$19.49

0.86 (4.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 06

    Feb

  • 08

    Feb

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

IRIX

IRIDEX

$7.46

-0.11 (-1.45%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Hot Stocks
BlueLine Partners reports 8.5% passive stake in IRIDEX »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLN

Olin

$37.04

0.155 (0.42%)

12:00
01/22/18
01/22
12:00
01/22/18
12:00
Options
Opening activity in Olin calls »

Opening activity in Olin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.